We have previously shown that MSDC-0160, a type 2 diabetes insulin sensitizer, can ameliorate pathology in an acute (1-methyl-4-phenyl-1,2,3,6-tetrahydro‌pyridine, MPTP) and slowly progressive, genetic (Engrailed1+/-) model of PD and that these effects occurred via modulation of the MPC and its downstream effect involving the mTOR pathway[10]. The gene discussed is MTOR; the disease is Parkinson disease.